GlaxoSmithKline Pharmaceuticals (GLAXO) — Financial Results

Investor Takeaways

Tax refund of ₹4.99 crores received post Income Tax assessment for AY 2025-2026.

Refund will be recorded under Tax Paid Assets with no impact on core financial performance.

No operational improvement or revenue growth indicated by the refund.

Overall Tone: Neutral based on the numbers only.

Key Financial Highlights

Metric	Value	YoY Change
Revenue	Not available	N/A
Net Profit	Not available	N/A
EBITDA	Not available	N/A
EPS	[amount context mismatch] (Q3FY25)	N/A
OPM	30.75% (Q3FY25)	N/A

What Changed

The filing discloses a one-time tax refund of ₹4.99 crores received on 18 August 2026, arising from an Income Tax notice related to assessment year 2025-2026. This amount will be recognized as a reduction in tax liabilities and recorded under Tax Paid Assets on the balance sheet. The company explicitly states this inflow has no operational impact or bearing on core financial performance. There is no mention of changes in revenue, profit, or margins directly attributable to this event. The refund is a non-recurring, administrative outcome of tax reassessment and does not reflect improved business activity or cost efficiency. All financial metrics in the filing remain unchanged by this event, with no restated figures for prior quarters.

Peer Comparison

Company	P/E	ROE	ROCE	Market Cap (₹ Cr)
GLAXO	48.31	Not available	Not available	41,314.74
SUNPHARMA	41.28	15.11%	20.34%	4,50,643.09
DIVISLAB	72.41	16.56%	22.09%	1,79,470.03
TORNTPHARM	80.06	N/A	N/A	1,49,108.91

GlaxoSmithKline Pharmaceuticals trades at a premium to Sun Pharmaceutical but below Divi's Laboratories in P/E, while lacking disclosed ROE and ROCE metrics. Its market capitalization is significantly lower than Sun Pharmaceutical but comparable to Divi's Laboratories.

Risks & Concerns

No specific risks identified in this filing.

Quarterly Trend

Quarter	Revenue (₹ Cr)	Net Profit (₹ Cr)	OPM%
Q3FY25	949.42	229.88	30.75
Q2FY25	1,010.77	252.5	31.83
Q1FY25	814.65	182.33	28.3
Q4FY24	929.8	194.48	27.67

📄 View Original Announcement (PDF)

📊 Stock Analysis — GLAXO ✨ Ask AI About This

About GlaxoSmithKline Pharmaceuticals Limited (GLAXO)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹51,721.36 Cr P/E: 49.2 ROE: 47.1% ROCE: 64.1% Div Yield: 1.87%

View full GLAXO stock details →

📡 Get AI alerts when GLAXO files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track GLAXO — Free

💡 Ask AI about this filing

"How does this refund impact the company's effective tax rate?" "What was the original tax liability before the refund?" "Are there pending tax assessments for other years?"

Ask AI Free →

📊 More GLAXO filings

See all GLAXO filings →

🔥 Also filed on 19 August 2026

ASALCBR Associated Alcohols & Breweries Ltd. Corporate Action SETUINFRA Setubandhan Infrastructure Limited Financial Results TIL TIL Limited Financial Results GOCOLORS Go Fashion (India) Limited Annual Report OIL Oil India Limited Corporate Action SRM SRM Contractors Limited Announcement

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when GLAXO files new disclosures

Track GLAXO filings, board meetings, and corporate actions. Free email alerts at 5 PM.